The Australian and New Zealand journal of psychiatry
-
Aust N Z J Psychiatry · Feb 2012
Randomized Controlled TrialTherapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.
Cerebrolysin is a nootropic drug with unique neurotrophic activities directly affecting cerebral neurons. This study evaluated the efficacy and safety of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. ⋯ Cerebrolysin added to risperidone did not augment the efficacy of risperidone in treating the psychotic symptoms of schizophrenia patients over an 8-week trial. Cerebrolysin at 30 ml per day as an adjunctive treatment was safe and may improve cognitive and memory functions of patients with schizophrenia dominated by negative symptoms.